In a significant development, iCAD, a prominent medical technology company, has been granted a device license by Health Canada for its ProFound Risk version 2.0. This innovative solution provides personalized breast cancer risk assessment, showcasing iCAD’s dedication to advancing medical technology in the field.
Designed to be compatible with both 2D and 3D mammography, ProFound Risk employs artificial intelligence to offer precise, individualized, and efficient risk assessments for women over the next one to two years. Importantly, this assessment can be conducted even for individuals exhibiting no current indications of breast cancer in their latest mammogram.
Utilizing a multifaceted approach, the technology incorporates diverse risk factors such as age, breast density, and subtle mammographic traits. This amalgamation allows medical professionals to tailor screening and intervention strategies based on the unique risk profile of each patient. By adopting this approach, the medical community can implement a more thorough and personalized method of detecting and evaluating breast cancer risks.
Dana Brown, the President and CEO of iCAD, expressed, “This regulatory endorsement underscores the clinical effectiveness of our technological solution, setting the stage for its integration within healthcare facilities across Canada. Given that breast cancer constitutes around 25% of new cancer cases and 13% of all cancer-related deaths among Canadian women, our technology bears the potential to address this significant challenge. By empowering medical practitioners to provide personalized care to patients at elevated risk of developing breast cancer in the upcoming 1-2 years, we aspire to enhance outcomes for women.”
Based in Nashua, New Hampshire, iCAD maintains a steadfast focus on delivering advanced solutions for cancer detection and therapy. The recent approval from Health Canada stands as a testament to iCAD’s commitment to transforming healthcare technology and contributing to improved patient outcomes.
